James D. Brooks
Academic Appointments
- Professor, Urology
- Member, Stanford Cancer Institute
- Member, Bio-X
Key Documents
Contact Information
-
Clinical Offices
Uro-Oncology Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 725-5544 Fax (650) 723-0765
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Urologic Oncology
- Male Cancers - Prostate
- Prostate Cancer
- Nerve-sparing radical prostatectomy
- Prostate Cancer - Urologic Oncology
- Urologic Cancers
Administrative Appointments
- Chief, Urologic Oncology, Department of Urology (2012 - present)
- Acting Chair, Department of Urology (2012 - 2012)
- Associate Chair, Prostate Cancer Working Group EDRN (2010 - present)
- Editor-in-Chief, The Open Prostate Cancer Journal (2008 - present)
- Editorial Board, Andrology (2011 - present)
- Editorial Board, Prostate Cancer (2010 - present)
Honors and Awards
- Keith and Jan Hurlbut Professor, Stanford University (2012)
- Listing in Guide to America's Top Surgeons, Consumers' Research Council (2010)
- Best Doctors in America, Best Doctors Inc. (2004-2013)
- Leutje-Stubbs Faculty Scholar, Stanford University School of Medicine (2002-2003)
- Eugene P. Schonfeld Medical Research Award, Kidney Cancer Association (2000-2002)
- Clinician Scientist Award, Doris Duke Foundation (1998-2002)
Professional Education
| Board Recertification: | Urology, American Board of Urology (2009) |
| Board Certification: | Urology, American Board of Urology (2000) |
| Internship: | Johns Hopkins University MD (1989) |
| Medical Education: | Stanford University School of Medicine CA (1988) |
| A. B.: | University of Chicago, Biology (1982) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
Our interest is in developing diagnostic and prognostic markers for urological diseases. We have approached this question broadly. We are active in biomarker discovery using genomic approaches. While our primary focus has been in prostate cancer, we have also worked in kidney bladder and testicular cancer. We are also actively seeking markers that reflect renal damage in patients with urinary obstruction. We are also interested in developing platforms for translating biomarkers discovered in the laboratory into clinical practice. For instance, we have active collaborations in developing novel molecular imaging strategies for prostate cancer. We also participate in several large clinical trials for development, validation and implementation of clinical biomarkers in prostate cancer.
Clinical Trials
- Recruiting Quality of Life Following Radical Prostatectomy
- Recruiting Prostate Active Surveillance Study
- Not Recruiting Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
- Not Recruiting Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
- Not Recruiting Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Publications
- A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013; (1): 39-44
- Comprehensive gene expression changes associated with mouse postnatal kidney development. J Urol. 2013; (6): 2385-90
- Epigenetic changes in histologically normal prostate tissues. J Urol. 2013; (6): 2020-1
- Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2. Appl Immunohistochem Mol Morphol. 2013
- Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene. 2013; (1): 70-7
- Treatment and mortality in men with localized prostate cancer: a population-based study in California. The Open Prostate Cancer Journal. 2013: 1-9
Help